Sanofi
Q3 2022 Earnings Call
Oct 28, 2022, 8:30 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Eva Schaefer-Jansen
Good morning, good afternoon, and good evening to everyone. Thank you for joining us to review Sanofi's 2022 third quarter results, followed by a Q&A session. As usual, you can find the slides to this earnings call on the Investors page of our website at sanofi.com. Moving to Slide 3.
I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. I refer you to our Form 20-F document on file with the SEC and also our Document d'enregistrement universel for a description of these risk factors. With that, please advance to Slide 4. Our speakers on the call today are Paul Hudson, chief executive officer; the global business unit heads, Bill Sibold, Thomas Triomphe, Olivier Charmeil, and Julie van Ongevalle; and Jean-Baptiste de Chatillon, chief financial officer.
[Operator instructions] With that, I'd like to turn the call over to Paul.
Paul Hudson -- Chief Executive Officer
Well, thank you, Eva, and thanks to everyone for joining. I'm truly delighted to show our outstanding financial results with you today. And as always, key members of the executive team are with me in the room to take you through the business and the financials. The strong performance of our businesses exceeded expectations with sales growing 9% at constant exchange rate.
Dupixent was once again the main driver within Specialty Care with robust growth in all markets and new indications. The next major waypoint of EUR 10 billion sales is now approaching and is achievable as soon as next year. To remind you, we introduced this submission only three years ago, when many of you considered this target to be, well, rather aggressive. Dupixent's unique profile in treating type two inflammatory diseases, coupled with our team's ability to execute launches, propel this exceptional medicine to new sales milestones while raising the bar for novel treatments in immunology.
This quarter marked another record Imvexxy sales, reaching EUR 3.3 billion, an increase of almost 24% from Q3 2021. Our success is primarily credited to our differentiated flu vaccines, exemplifying our unparalleled leadership in this field. Two-thirds of our global flu sales in Q3 were generated by our high-dose flu brands, reflecting the recognition by payers and providers of this superior value and protection beyond flu. Higher sales were also driven by our capacity to speedily manufacture and supply the vaccines to our customers.